Morgan Stanley Reiterates Equal-Weight on Abbott Laboratories, Maintains $112 Price Target
Portfolio Pulse from Benzinga Newsdesk
Morgan Stanley analyst David Lewis has reiterated an Equal-Weight rating on Abbott Laboratories (NYSE:ABT) and maintained a $112 price target.
July 21, 2023 | 1:05 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Morgan Stanley has reiterated an Equal-Weight rating on Abbott Laboratories and maintained a $112 price target.
The news is directly about Abbott Laboratories. Morgan Stanley's reiteration of an Equal-Weight rating and maintenance of a $112 price target indicates a neutral outlook for the stock in the short term.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 100